Aridis Pharmaceuticals (NASDAQ:ARDS) enrolled the first COVID-19 patient in its ongoing Phase 3 trial of AR-301 for ventilator-associated pneumonia.
Initiated in the first quarter of 2019, the Phase 3 study will assess AR-301, a monoclonal antibody targeting gram-positive S. aureus alpha-toxin, in some 240 patients at 160 clinical centers worldwide.
“While AR-301 does not treat the virus that causes COVID-19 disease, it can potentially mitigate secondary S. aureus bacterial pneumonia, which represents a serious coronavirus complication and a cause of death in such patients,” Vu Truong, Aridis’ CEO, said in a statement.
